Literature DB >> 24331287

Functional impairment in patients with major depressive disorder and comorbid anxiety disorder.

Margalida Gili1, Mauro García Toro1, Silvia Armengol2, Javier García-Campayo3, Adoración Castro4, Miquel Roca1.   

Abstract

OBJECTIVE: To analyze the potential for different aspects of anxiety to modify the effect of impaired functioning in major depressive disorder (MDD).
METHODS: Participants (n = 1226) were psychiatric outpatients with MDD. A cross-sectional, multicentre, nationwide study was designed. The 12-item version of the World Health Organization Disability Assessment Schedule II was used to assess functional limitation. Anxiety was measured using the Hamilton Anxiety Rating Scale and the State-Trait Anxiety Inventory (STAI). Depression severity was measured using the Quick Inventory of Depressive Symptomatology.
RESULTS: About 43.1% of patients had a comorbid MDD and anxiety disorder. Poorer functioning correlated significantly with severity of depression (Pearson r = 0.78, P = 0.001), severity of anxiety (r = 0.65, P = 0.001), and higher anxiety trait scores (r = 0.40, P = 0.001), but not significantly with STAI-State scores (r = 0.03, P = 0.26). The overall regression model was significant and explained 66% of the functioning variability in patients with MDD, mostly attributable to depression severity. Results indicate that anxiety has a moderate impact on functioning impairment in patients with MDD.
CONCLUSIONS: Our findings suggest that MDD and anxiety severity appear to be associated significantly with impaired functioning in patients with MDD but explains only a moderate proportion of variance.

Entities:  

Keywords:  anxiety; comorbidity; depression; disability; functional impairment

Mesh:

Year:  2013        PMID: 24331287     DOI: 10.1177/070674371305801205

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  13 in total

1.  A Randomized, Placebo-Controlled Pilot Study of Quetiapine-XR Monotherapy or Adjunctive Therapy to Antidepressant in Acute Major Depressive Disorder with Current Generalized Anxiety Disorder.

Authors:  Ranran Li; Renrong Wu; Jun Chen; David E Kemp; Ming Ren; Carla Conroy; Philip Chan; Mary Beth Serrano; Stephen J Ganocy; Joseph R Calabrese; Keming Gao
Journal:  Psychopharmacol Bull       Date:  2016-03-01

2.  The functional burden of diabetic retinopathy in the United States.

Authors:  Dipal Nagda; William Mitchell; Nazlee Zebardast
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-04-29       Impact factor: 3.117

Review 3.  Depressive symptoms in neurodegenerative diseases.

Authors:  Miquel Baquero; Nuria Martín
Journal:  World J Clin Cases       Date:  2015-08-16       Impact factor: 1.337

4.  Study of Functional Impairment in Students of Elementary and Secondary Public Schools in Iran.

Authors:  Habib Hadianfard; Behnaz Kiani; Margaret D Weiss
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2021-05-01

5.  Psychiatric comorbidities in patients with major depressive disorder.

Authors:  Papan Thaipisuttikul; Pichai Ittasakul; Punjaporn Waleeprakhon; Pattarabhorn Wisajun; Sudawan Jullagate
Journal:  Neuropsychiatr Dis Treat       Date:  2014-11-10       Impact factor: 2.570

6.  A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression.

Authors:  Hiroko Sugawara; Kaoru Sakamoto; Tsuyoto Harada; Satoru Shimizu; Jun Ishigooka
Journal:  Neuropsychiatr Dis Treat       Date:  2016-05-10       Impact factor: 2.570

7.  Transdiagnostic Tailored Internet- and Mobile-Based Guided Treatment for Major Depressive Disorder and Comorbid Anxiety: Study Protocol of a Randomized Controlled Trial.

Authors:  Kiona K Weisel; Anna-Carlotta Zarski; Thomas Berger; Michael P Schaub; Tobias Krieger; Christian T Moser; Matthias Berking; David D Ebert
Journal:  Front Psychiatry       Date:  2018-07-04       Impact factor: 4.157

8.  Age-Related Macular Degeneration and Visual and Physical Disability in a Nationally Representative Sample from the United States.

Authors:  William Mitchell; Hannah Resnick; Nazlee Zebardast
Journal:  Transl Vis Sci Technol       Date:  2020-12-28       Impact factor: 3.283

9.  Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety.

Authors:  Gang Wang; Xiumin You; Xueyi Wang; Xiufeng Xu; Ludong Bai; Jian Xie; Zhijian Yao; QiZhong Yi; Jun Ma; Jinan Wang; Jianmin Zhuo; Cuili Hu
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-14       Impact factor: 2.570

10.  Recognition of personality disorder and anxiety disorder comorbidity in patients treated for depression in secondary psychiatric care.

Authors:  Marie Asp; Daniel Lindqvist; Johan Fernström; Livia Ambrus; Eva Tuninger; Margareta Reis; Åsa Westrin
Journal:  PLoS One       Date:  2020-01-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.